Implementing CADR Requirements for NIH Websites: A Case Study
The white paper is now publicly available at:
https://bsisystems.com/bioshare/cadr/Implementing-NIH-CADR_IMS-BioShare.pdf
Co‑authored by
"Scientific progress depends on responsible data sharing, but that sharing must occur within a secure, well‑governed environment," said Carroll. "This paper demonstrates how BioShare enables organizations to adopt NIH‑aligned CADR security standards quickly and with minimal operational disruption."
The white paper highlights key upgrades made to BioShare, including:
- Integration of Identity Assurance Level 2 (IAL2) authentication and stricter institutional validation requirements.
- Expanded Data Access Committee (DAC) review workflows with role‑based permissions.
- Standardized Data Use Agreement (DUA) management with automated 12‑month access expiration enforcement and optional electronic signatures.
- Strengthened secure data delivery through project‑specific permissions, controlled download timeframes, and detailed logs.
- Support for hosting environments aligned with federal moderate‑level security guidelines.
"BioShare's configurable architecture allowed us to rapidly integrate new NIH requirements without redevelopment or major downtime," noted Hacker. "It demonstrates what a forward‑compatible CADR platform can look like."
BioShare is currently used by multiple research and government programs to enable secure, streamlined access to controlled datasets and biospecimens. Its integrated workflows for request management, governance, and security help research organizations meet compliance obligations while maintaining a user‑friendly experience for investigators.
The full white paper can be accessed at https://bsisystems.com/bioshare/cadr/Implementing-NIH-CADR_IMS-BioShare.pdf.
View original content to download multimedia:https://www.prnewswire.com/news-releases/implementing-cadr-requirements-for-nih-websites-a-case-study-302734884.html
SOURCE Information Management Services, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
- Best Crypto Presale 2026: JPMorgan Adds Two Funds to Solana as Remittix Recruits 100 Earn Testers
- Beyond GRC: DigitalXForce Pioneers AI-Powered Risk Operations with Global X-ROC™ Rollout
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share